HIV-1 tropism and survival in vertically infected Ugandan infants.

BACKGROUND Human immunodeficiency virus type 1 (HIV-1) may utilize the CXCR4 coreceptor (X4 virus), the CCR5 coreceptor (R5 virus), or both (dual/mixed [DM] virus). We analyzed HIV-1 coreceptor tropism in Ugandan infants enrolled in the HIVNET (HIV Network for Prevention Trials) 012 trial. METHODS Plasma or serum was analyzed using a commercial coreceptor tropism assay. HIV env subtype was determined by phylogenetic methods. RESULTS Tropism results were obtained for 57 samples from infants collected 6-14 weeks after birth. Fifty-two infants had only R5 virus, and 5 had either X4 or DM virus. The mothers of those 5 infants also had X4 or DM virus. In infants, subtype D infection was associated with high-level infectivity in CCR5-bearing cells and also with the detection of X4 or DM strains. High-level infectivity in CCR5-bearing cells was associated with decreased infant survival, but infection with X4 or DM virus was not. HIV clones from infants with DM viral populations showed different patterns of coreceptor use. V3 loop sequence-based algorithms predicted the tropism of some, but not all, env clones. CONCLUSIONS Complex patterns of HIV tropism were found in HIV-infected newborn infants. Subtype D infection was associated with X4 virus and with high-level replication in CCR5-bearing cells. High-level replication of R5 virus was associated with decreased infant survival.

[1]  Christos J. Petropoulos,et al.  Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2006, Antimicrobial Agents and Chemotherapy.

[2]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial , 2003, The Lancet.

[3]  T. Leitner,et al.  Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. , 2002, The Journal of infectious diseases.

[4]  L. Kalish,et al.  Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. , 1997, The New England journal of medicine.

[5]  B. Burkhardt,et al.  Complex Determinants in Human Immunodeficiency Virus Type 1 Envelope gp120 Mediate CXCR4-Dependent Infection of Macrophages , 2005, Journal of Virology.

[6]  P. Kaleebu,et al.  Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D: Results From a Rural Ugandan Cohort , 2007, Journal of acquired immune deficiency syndromes.

[7]  Oliver Hartley,et al.  V3: HIV's switch-hitter. , 2005, AIDS research and human retroviruses.

[8]  L. Mofenson,et al.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) , 2001, AIDS.

[9]  Lynn Morris,et al.  A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences , 2006, Journal of Virology.

[10]  P. Musoke,et al.  Survival of Ugandan Infants with Subtype A and D HIV‐1 Infection (HIVNET 012) , 2002, Journal of acquired immune deficiency syndromes.

[11]  Eoin Coakley,et al.  Assessing chemokine co-receptor usage in HIV , 2005, Current opinion in infectious diseases.

[12]  G. Scarlatti,et al.  HIV type 1 chemokine receptor usage in mother-to-child transmission. , 2001, AIDS research and human retroviruses.

[13]  S. Kwok,et al.  Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: importance of viral RNA and the timing of transmission on long-term outcome. , 1998, The Journal of infectious diseases.

[14]  J. Margolick,et al.  Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.

[15]  W. Andiman,et al.  Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. , 2002, AIDS research and human retroviruses.

[16]  J. Fitzgibbon,et al.  Effect of the HIV‐1 syncytium‐inducing phenotype on disease stage in vertically‐infected children , 1998, Journal of medical virology.

[17]  F. Dabis,et al.  Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children. , 2003, Pediatrics.

[18]  L. Ratner,et al.  Human Immunodeficiency Virus Type 1 Coreceptor Switching: V1/V2 Gain-of-Fitness Mutations Compensate for V3 Loss-of-Fitness Mutations , 2006, Journal of Virology.

[19]  J. Moye,et al.  The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. , 1997, The Journal of infectious diseases.

[20]  L. Ratner,et al.  Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants , 1996, Journal of virology.

[21]  T. Hahn,et al.  Biological characterization of HIV type 1 envelope V3 regions from mothers and infants associated with perinatal transmission. , 2001, AIDS research and human retroviruses.

[22]  J. Albert,et al.  Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. , 1993, Virology.

[23]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[24]  Noah G. Hoffman,et al.  Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop , 2002, Journal of Virology.

[25]  T. Leitner,et al.  Coreceptor change appears after immune deficiency is established in children infected with different HIV-1 subtypes. , 2002, AIDS research and human retroviruses.

[26]  F. Barré-Sinoussi,et al.  Coreceptor Usage of HIV‐1 Isolates Representing Different Genetic Subtypes Obtained From Pregnant Cameroonian Women , 2000, Journal of acquired immune deficiency syndromes.

[27]  Bhavna Chohan,et al.  HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. , 2007, The Journal of infectious diseases.

[28]  Wei Huang,et al.  Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations , 2007, Journal of Virology.

[29]  J. Albert,et al.  Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.

[30]  L. Mofenson,et al.  The Relationship between Serum Human Immunodeficiency Virus Type 1 (HIV-1) RNA Level, CD4 Lymphocyte Percent, and Long-Term Mortality Risk in HIV-1—Infected Children , 1997 .

[31]  Sudhir Kumar,et al.  MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment , 2004, Briefings Bioinform..

[32]  Kees,et al.  Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. , 1994, The Journal of clinical investigation.

[33]  J. Goudsmit,et al.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.

[34]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[35]  Charles Wood,et al.  Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. , 2002, AIDS research and human retroviruses.